Bluejay Diagnostics (BJDX) Non-Current Deferred Tax Liability (2020 - 2021)
Bluejay Diagnostics' (BJDX) quarterly Non-Current Deferred Tax Liability came in at $26860.0 in Q4 2021, down 63.32% year-on-year from $73232.0 in Q4 2020, and down 63.32% quarter-over-quarter from $73232.0 in Q4 2020.
Bluejay Diagnostics (BJDX) Non-Current Deferred Tax Liability (2020 - 2021) Analysis & Trends
Bluejay Diagnostics has disclosed Non-Current Deferred Tax Liability across 2 years of filings, most recently posting $26860.0 for Q4 2021.
- Non-Current Deferred Tax Liability for Q4 2021 came in at $26860.0, down 63.32% year-over-year; the trailing twelve-month figure through Dec 2021 was $26860.0 (down 63.32% YoY), and the FY2021 annual result was $26860.0, down 63.32% from the prior year.
- Non-Current Deferred Tax Liability came in at $26860.0 for Q4 2021 at Bluejay Diagnostics, down from $73232.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $73232.0 in Q4 2020 to a low of $26860.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Bluejay Diagnostics | 4.43 Mn | 746,549.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 26,860.00 |
| Dec 31, 2021 | 26,860.00 |
| Dec 31, 2020 | 73,232.00 |
| Dec 31, 2020 | 73,232.00 |